Options
The preclinical discovery and development of opicapone for the treatment of Parkinson’s disease
Fecha de emisión
2020
Autor(es)
Ettcheto M.
Busquets O.
Sánchez-Lopez E.
Cano A.
Manzine P.R.
Verdaguer E.
Olloquequi J.
Auladell C.
Folch J.
Camins A.
DOI
10.1080/17460441.2020.1767580
Temas
dyskinesia
entacapone
Opicapone
Parkinson’s disease
tolcapone
opicapone
Article
cardiotoxicity
clinical study
constipation
dizziness
drug approval
drug efficacy
drug half life
drug marketing
drug mechanism
drug research
drug safety
drug tolerability
dyskinesia
evaluation study
human
insomnia
liver toxicity
maximum concentration...
motor performance
nonhuman
Parkinson disease
pharmacokinetic param...
pharmacological param...
preclinical study
priority journal
side effect
systematic review
xerostomia
Archivo(s)